Erythroid-specific Expression of Beta-globin by the Sleeping Beauty Transposon for Sickle Cell Disease
Overview
Affiliations
Sickle cell disease (SCD) results predominately from a single monogenic mutation that affects thousands of individuals worldwide. Gene therapy approaches have focused on using viral vectors to transfer wild-type beta- or gamma-globin transgenes into hematopoietic stem cells for long-term expression of the recombinant globins. In this study, we investigated the use of a novel nonviral vector system, the Sleeping Beauty (SB) transposon (Tn) to insert a wild-type beta-globin expression cassette into the human genome for sustained expression of beta-globin. We initially constructed a beta-globin expression vector composed of the hybrid cytomegalovirus (CMV) enhancer chicken beta-actin promoter (CAGGS) and full-length beta-globin cDNA, as well as truncated forms lacking either the 3' or 3' and 5' untranslated regions (UTRs), to optimize expression of beta-globin. Beta-globin with its 5' UTR was efficiently expressed from its cDNA in K-562 cells induced with hemin. However, expression was constitutive and not erythroid-specific. We then constructed cis SB-Tn-beta-globin plasmids using a minimal beta-globin gene driven by hybrid promoter IHK (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, ankyrin-1 promoter), IHbetap (human ALAS2 intron 8 erythroid-specific enhancer, HS40 core element from human alphaLCR, beta-globin promoter), or HS3betap (HS3 core element from human betaLCR, beta-globin promoter) to establish erythroid-specific expression of beta-globin. Stable genomic insertion of the minimal gene and expression of the beta-globin transgene for >5 months at a level comparable to that of the endogenous gamma-globin gene were achieved using a SB-Tn beta-globin cis construct. Interestingly, erythroid-specific expression of beta-globin driven by IHK was regulated primarily at the translational level, in contrast to post-transcriptional regulation in non-erythroid cells. The SB-Tn system is a promising nonviral vector for efficient genomic insertion conferring stable, persistent erythroid-specific expression of beta-globin.
Dormiani K, Sadeghi H, Sadeghi-Aliabadi H, Ghaedi K, Forouzanfar M, Baharvand H Gene Ther. 2015; 22(8):663-74.
PMID: 25830551 DOI: 10.1038/gt.2015.30.
Genomic analysis of Sleeping Beauty transposon integration in human somatic cells.
Turchiano G, Latella M, Gogol-Doring A, Cattoglio C, Mavilio F, Izsvak Z PLoS One. 2014; 9(11):e112712.
PMID: 25390293 PMC: 4229213. DOI: 10.1371/journal.pone.0112712.
Sjeklocha L, Wong P, Belcher J, Vercellotti G, Steer C PLoS One. 2013; 8(11):e80403.
PMID: 24260386 PMC: 3832362. DOI: 10.1371/journal.pone.0080403.
A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitro.
Ding G, Chen X, Zhu J, Duesbery N, Cheng X, Cao B Clin Dev Immunol. 2013; 2013:475809.
PMID: 23861692 PMC: 3687597. DOI: 10.1155/2013/475809.
Restoration of dystrophin expression using the Sleeping Beauty transposon.
Muses S, Morgan J, Wells D PLoS Curr. 2012; 3:RRN1296.
PMID: 22318674 PMC: 3269885. DOI: 10.1371/currents.RRN1296.